[Market Focus] Samsung Biologics and Episholdings Weaken Together on First Day After Spin-off and Relisting

After the spin-off and relisting, both Samsung Biologics and the newly established Samsung Episholdings are experiencing declines.

As of 9:54 a.m. on the 24th, Samsung Biologics is trading at 1,669,000 won, down 128,000 won (7.12%) from the previous session. Samsung Episholdings is at 498,500 won, down 112,500 won (18.41%) from its opening price of 611,000 won.

Previously, Samsung Biologics underwent a spin-off into a surviving company (Samsung Biologics), which continues its contract development and manufacturing organization (CDMO) business, and a new company (Samsung Episholdings) responsible for investments and subsidiary management. Samsung Bioepis is in charge of the biosimilar business and new drug development.